of first-line therapeutic agents. [1] IBD is tightly associated with dysbiosis of the gut microbiome, characterized by an increase in facultative anaerobic bacteria of Enterobacteriaceae and a decrease in beneficial bacteria. [2] Extensive studies have shown that gut microbiome dysbiosis plays a critical role in the etiology of IBD, and some commensal microbiomes also manifest anti-inflammatory activity to an extent. [3] Consequently, the exploitation of therapies that can reprogram the gut microbiome to treat IBD has been suggested. Various therapies have been applied to reprogram the microbiome, including enteral nutrition, fecal microbiota transplantation, prebiotics, probiotics, and postbiotic supplements. [4] Although considerable efforts have been made, the therapeutic effects of these treatments remain hampered by the non-specificity of the treatment and the enormous growth of pathogenic microbiota. [2c,5] As Escherichia coli occupies several ecological niches during IBD owing to abnormal expansion, beneficial bacteria can establish ecological niches by restricting the proliferation of E. coli. [2c,6] Traditional medical therapies for IBD have centered on broad-spectrum antibiotics to prevent the expansion of pathogenic bacteria. [4a] However, the use of antibiotics also destroys probiotics and increases the risk of antibiotic-induced Therapeutic approaches that reprogram the gut microbiome are promising strategies to alleviate and cure inflammatory bowel disease (IBD). However, abnormal expansion of Escherichia coli during inflammation can promote pathogenic bacteria occupying ecological niches to resist reprogramming of the microbiome. Herein, a bionic regulator (CaWO 4 @YCW) is developed to efficiently and precisely regulate the gut microbiome by specifically suppressing the abnormal expansion of E. coli during colitis and boosting probiotic growth. Inspired by the binding of E. coli strains to the mannoserich yeast cell wall (YCW), YCW is chosen as the bionic shell to encapsulate CaWO 4 . It is demonstrated that the YCW shell endows CaWO 4 with superior resistance to the harsh environment of the gastrointestinal tract and adheres to the abnormally expanded E. coli in colitis, specifically as a positioner. Notably, the high expression of calprotectin at the colitis site triggers the release of tungsten ions through calcium deprivation in CaWO 4 , thus inhibiting E. coli growth by replacing molybdenum in the molybdopterin cofactor. Moreover, YCW functions as a prebiotic and promotes probiotic growth. Consequently, CaWO 4 @YCW can efficiently and precisely reprogram the gut microbiome by eliminating pathogenic bacteria and providing prebiotics, resulting in an extraordinary therapeutic advantage for DSS-induced colitis.